EIPICO starts MUP stake acquisition: what it means for PHAR stock

Published on 10/14/2026 at 06:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EIPICO is assessing a 9.77 percent MUP stake valued above EGP 200 million. For PHAR stock, it reports 117 pipeline programs and 5,000 employees.

Acquisition and operating scale

EIPICO began measures for a 9.77 percent MUP stake valued above EGP 200 million.
The company reports 117 pipeline programs and more than 400 products.
EIPICO opened a factory facility on July 27, 2026.

PHAR, EGS38081C013, Illustration mit AI erstellt.

Egyptian International Pharmaceutical Industries, known as EIPICO, started measures to acquire a 9.77 percent stake in Medical Union Pharmaceuticals for more than EGP 200 million, according to Daily News Egypt in an October 2026 report. The transaction would expand EIPICO's existing 9.77 percent holding in Medical Union Pharmaceuticals, while PHAR stock remains linked to a company with 117 pipeline programs and more than 400 products.

Three developments shape EIPICO

On July 27, 2026, EIPICO reported a factory opening, according to ESTHMR. The company website lists 46 manufacturing lines and exports to 78 countries, giving the acquisition plan an operating context beyond the stake percentage.

On August 13, 2026, EIPICO reported second-quarter and six-month results for the period ended June 30, 2026, according to MarketScreener. That reporting milestone preceded the acquisition measures and provides the latest dated results reference identified for the company.

What does the acquisition mean?

The proposed stake purchase matters because EIPICO already holds 9.77 percent of Medical Union Pharmaceuticals, according to Daily News Egypt, and the new measures would deepen that investment. EIPICO's own website reports 5,000 employees, 25 therapeutic classes and a 24 percent share of Egypt's pharmaceutical exports by value, figures that frame the deal as part of a broader manufacturing and export platform.

Operating scale stays central

EIPICO says it has 117 pipeline programs and 65 new products on its corporate website. Its portfolio also includes 400 products across 25 therapeutic classes, while the company describes its EIPICO 3 facility as focused on biological and biosimilar manufacturing.